16 production sites on 5 continents.
Affiliates or offices in 77 countries.
Products marketed in more than 165 countries.
Approximately 41,700 employees (FTEs September 2017).
19% within research and development
32% in production and production administration
37% in international sales and marketing
12% in administration
Regional distribution (FTEs)
Approximately 41% of employees are located in Denmark (17,105 FTEs) and 59% in the rest of the world:
Africa, Asia, Middle East & Oceania: 6,627
China (4,206) & Taiwan: 4,299
Europe (excl. HQ): 4,312
Japan (1,124) & Korea: 1,248
Latin America: 1,805
North America (US 5,961 & Canada 299): 6,260
(includes all Novo Nordisk and NNE employees in the respective locations)
According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.
For patient and disease information, including pens and needles, please look under Patients.
26,614 million Danish kroner
Sales by business segment
Diabetes and obesity care total:
21,563 million Danish kroner
4,411 million Danish kroner
Sales by region
North America Operations:
13,532 million Danish kroner
USA: 12,967 million Danish kroner
13,082 million Danish kroner
Region Europe: 5,190 million Danish kroner
Region AAMEO: 2,929 million Danish kroner
Region China: 2,531 million Danish kroner
Region Japan & Korea: 1,462 million Danish kroner
Region Latin America: 970 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90